These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 11200057

  • 21. Expression of transforming growth factor beta (TGF-beta1) in human epithelial alveolar cells: a pro-inflammatory mediator independent pathway.
    Kwong KY, Literat A, Zhu NL, Huang HH, Li C, Jones CA, Minoo P.
    Life Sci; 2004 Apr 30; 74(24):2941-57. PubMed ID: 15051419
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells.
    Harizi H, Norbert G.
    Cell Immunol; 2004 Apr 30; 228(2):99-109. PubMed ID: 15219461
    [Abstract] [Full Text] [Related]

  • 23. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, Chander MC, Baker SD, He L, Horwitz SB, Swindell CS.
    Clin Cancer Res; 2001 Oct 30; 7(10):3229-38. PubMed ID: 11595719
    [Abstract] [Full Text] [Related]

  • 24. Induction of soluble antitumoral mediators by synthetic analogues of bacterial lipoprotein in bone marrow-derived macrophages from LPS-responder and -nonresponder mice.
    Pfannes SD, Müller B, Körner S, Bessler WG, Hoffmann P.
    J Leukoc Biol; 2001 Apr 30; 69(4):590-7. PubMed ID: 11310845
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction.
    Bellinghausen I, König B, Böttcher I, Knop J, Saloga J.
    Clin Exp Allergy; 2006 Dec 30; 36(12):1546-55. PubMed ID: 17177678
    [Abstract] [Full Text] [Related]

  • 26. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
    Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L.
    Cancer Res; 2006 Sep 15; 66(18):9290-8. PubMed ID: 16982774
    [Abstract] [Full Text] [Related]

  • 27. Tumor growth modulates macrophage nitric oxide production following paclitaxel administration.
    Mullins DW, Burger CJ, Elgert KD.
    Int J Immunopharmacol; 1998 Oct 15; 20(10):537-51. PubMed ID: 9839658
    [Abstract] [Full Text] [Related]

  • 28. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
    Clin Cancer Res; 2005 Jun 15; 11(12):4512-20. PubMed ID: 15958637
    [Abstract] [Full Text] [Related]

  • 29. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7.
    Wang W, Huang XR, Li AG, Liu F, Li JH, Truong LD, Wang XJ, Lan HY.
    J Am Soc Nephrol; 2005 May 15; 16(5):1371-83. PubMed ID: 15788474
    [Abstract] [Full Text] [Related]

  • 30. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis.
    Weeks BH, He W, Olson KL, Wang XJ.
    Cancer Res; 2001 Oct 15; 61(20):7435-43. PubMed ID: 11606377
    [Abstract] [Full Text] [Related]

  • 31. Effects of taxol on the macrophage function. Interactions with some immunological parameters.
    Bottex-Gauthier C, Condemine F, Picot F, Vidal D.
    Immunopharmacol Immunotoxicol; 1992 Oct 15; 14(1-2):39-61. PubMed ID: 1350792
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Tumor-derived cytokines dysregulate macrophage interferon-gamma responsiveness and interferon regulatory factor-8 expression.
    Mullins DW, Martins RS, Elgert KD.
    Exp Biol Med (Maywood); 2003 Mar 15; 228(3):270-7. PubMed ID: 12626771
    [Abstract] [Full Text] [Related]

  • 35. Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha.
    Seong J, Milross CG, Hunter NR, Shin HC, Milas L.
    Anticancer Drugs; 1997 Jan 15; 8(1):80-7. PubMed ID: 9147616
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer.
    Jiang X.
    J Zhejiang Univ Sci B; 2015 Jan 15; 16(1):44-5. PubMed ID: 25559954
    [No Abstract] [Full Text] [Related]

  • 39. Transfection of TGF-beta producing tumors with IL-2 elicits tumor rejection.
    Lord E, McAdam A, Felcher A, Woods M, Pulaski B, Hutter E, Frelinger J.
    Ann N Y Acad Sci; 1993 Aug 12; 690():346-8. PubMed ID: 8368752
    [No Abstract] [Full Text] [Related]

  • 40. Roles for CD8+ T Cells and IL-10 in the Resolution of Paclitaxel-Induced Neuropathic Pain.
    Bravo-Caparrós I, Nieto FR.
    J Neurosci; 2017 Mar 15; 37(11):2803-2805. PubMed ID: 28298569
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.